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Introduction: Different mesenchymal stromal cells (MSC) have been successfully isolated and expanded in vitro and
nowadays they are tested in clinical trials for a wide variety of diseases. Whether all MSC express the same cell
surface markers or have a similar secretion profile is still controversial, making it difficult to decide which stromal
cell may be better for a particular application.
Methods: We isolated human mesenchymal stromal cells from bone marrow (BM), adipose tissue (AT) and
Wharton’s jelly (WJ) and cultured them in fetal bovine serum supplemented media. We evaluated proliferation,
in vitro differentiation (osteogenic, adipogenic and chondrogenic potential), expression of cell surface markers and
protein secretion using Luminex and ELISA assays.
Results: Cell proliferation was higher for WJ-MSC, followed by AT-MSC. Differences in surface expression markers
were observed only for CD54 and CD146. WJ-MSC secreted higher concentrations of chemokines, pro-inflammatory
proteins and growth factors. AT-MSC showed a better pro-angiogenic profile and secreted higher amounts of
extracellular matrix components and metalloproteinases.
Conclusions: Mesenchymal stromal cells purified from different tissues have different angiogenic, inflammatory and
matrix remodeling potential properties. These abilities should be further characterized in order to choose the best
protocols for their therapeutic use.Introduction
Mesenchymal stromal cells (MSC) are a small popula-
tion of multipotent progenitor cells present in nearly all
human tissues, being mostly found in the perivascular
niche [1]. MSC were first isolated from bone marrow
[2], but they have been obtained subsequently from a
wide variety of fetal and adult tissues: adipose tissue [3],
placenta [4], lung [5], umbilical cord [6], synovial mem-
brane [7] and dental pulp [8] among many others.
Regenerative medicine makes use of MSC and of their
multipotent properties to promote tissue regeneration.
MSC are able to migrate into injured tissues, engraft and
differentiate into many cell types, participating thus directly* Correspondence: pramable@gmail.com
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crine mediators, reducing inflammation and accelerating
tissue regeneration by activation of resident stem cells and
mobilization of circulating systemic stem cells through
chemotactic signaling [10,11]. Clinical trials have already
confirmed that use of MSC is safe and effective [12]. Even
when MSC express major histocompatibility complex
class I, they proved to be safe in allogeneic transplants, also
between HLA-incompatible individuals, since they do not
elicit alloreactive lymphocyte proliferative responses
in vitro, they produce locally immunomodulatory proteins
and their expression levels of major histocompatibility com-
plex class II are negligible [13,14].
Studies comparing MSC derived from different tissues
are limited to in vitro and pre-clinical studies. Clinical
trials are generally focused on safety and efficiency of a
therapy using a specific type of MSC, without demon-
strating which MSC is the best for each therapy, or evenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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best option. Basic MSC comparative studies are required
to better understand MSC properties and abilities, indi-
cating the most appropriate MSC type for a particular
clinical application.
In vitro studies have already shown that MSC from
different origins varied when considering differentiation
potential: some cells are better for differentiation into
osteoblast-like cells [15], while synovium-derived MSC
and umbilical cord-derived MSC are better differentiated
into chondrocytes than the bone marrow-derived MSC
[16,17]. MSC isolated from fetal tissues are superior re-
garding cardiomyocyte and endothelial cell differenti-
ation when compared to adult tissue-derived MSC [18].
Besides differentiation potential, recent studies have
approached other MSC attributes that allowed a deeper
understanding of tissue-derived properties. Hsieh and
colleagues compared MSC derived from Wharton’s Jelly
and bone marrow regarding their ability to regenerate
infarcted myocardia; they described secretome differ-
ences that make Wharton’s Jelly-derived MSC a more an-
giogenic, neuroprotective and neurogenic option [19].
Naftali-Shani and coworkers carried out a pre-clinical trial
of myocardial infarction in rats comparing the effects of
human stromal cells obtained from four locations (epicar-
dial fat, pericardial fat, subcutaneous fat and the right
atrium) and they showed that hMSCs from epicardial
fat and the right atrium secreted the highest amounts of
trophic and inflammatory cytokines in vitro, expressed
higher amounts of inflammation- and fibrosis-related genes
in vitro and impaired heart recovery in vivo [20]. Research
studies like these mentioned here are essential for deter-
mining the best tissue-derived mesenchymal stromal cell
for a particular regenerative therapy strategy.
In the present study, we compared three different cell
types: MSC derived from bone marrow, adipose tissue and
Wharton’s Jelly with the purpose to better understand
their differences and similarities. We monitored prolifera-
tion, differentiation into mesodermal cell types and cell
surface marker expression. We also quantified production
and secretion of cytokines, chemokines, growth factors




All the experimental procedures were done after Ethics
Research Committees approval and all donors signed
an informed consent. Adipose tissue-derived MSC (AT-
MSC) were obtained from abdominal liposuction during
plastic surgery (age: 53.8 ± 5.4 years; sex: 50/50% male/
female; CEP No. 55219/12, Research Ethics Committee
of Pro-Cardíaco Hospital, Rio de Janeiro, Brazil). Wharton’s
Jelly-derived MSC (WJ-MSC) were obtained from umbilicalcords of full-term cesarean births (38 to 39 weeks; CEP
No. 336/10, Research Ethics Committee of Pro-Cardíaco
Hospital, Rio de Janeiro, Brazil). Bone marrow-derived
MSC (BM-MSC) were purified from bone marrow har-
vested from posterior iliac crests during orthopedic surgery
(age: 55.5 ± 13.4 years; sex: 50/50% male/female; CEP
No. 473/12, Research Ethics Committee of Pro-Cardíaco
Hospital, Rio de Janeiro, Brazil).
Cell isolation and culture
Stromal cells were isolated as previously described [21].
Briefly, nucleated cells were separated from human
bone marrow using Ficoll-Paque™ PLUS (GE Healthcare,
Uppsala, Uppsala, Sweden, #17-1440-02) by density gradi-
ent centrifugation at 700 g during a 15-minute period.
After washing cells with phosphate-buffered saline (PBS -
LGC, Cotia, São Paulo, Brazil, #13-30259-05), they were
plated in T25 flasks in alpha-Minimum Essential Medium
(α-MEM - LGC, BR30007-05) supplemented with 10%
fetal bovine serum (FBS - LGC, #10-BIO-500). Human
adipose tissue was washed three times with PBS and was
treated with 1.76 mg collagenase type I/gram tissue
(Sigma-Aldrich, St. Louis, Missouri, USA, C9891) for 30
minutes at 4°C and 30 minutes at 37°C with agitation.
After proteolytic activity inhibition and centrifugation (700
g, seven minutes), pelleted cells were plated in T25 flasks.
Human umbilical cords were washed with PBS and blood
vessels were removed. Wharton’s jelly was cut into small
pieces and digested with 0.9 mg collagenase type II/gram
tissue (Sigma, C6885) at 37°C for one hour. Washed cells
were centrifuged at 700 g for seven minutes and plated in
T25 flasks. All cells were expanded up to passage number
3 in order to obtain a higher number of cells and were then
cryopreserved.
For all the experiments, cells obtained from four dif-
ferent donors in the same passage number were thawed
and mixed in order to prepare cell pools, which were
immediately plated for proliferation experiments.
Proliferation curves
Cells of each cell pool were seeded in 24-well plates at a
concentration of 6,000 cells/mL in α-MEM supplemented
with 10% FBS. Cells grown in different wells were trypsi-
nized and counted in a Neubauer hemocytometer at three
different times: 96, 144 and 192 hours.
Flow cytometry
After cell detachment using a 0.125% trypsin solution, cells
were washed with PBS and resuspended in PBS containing
2% FBS. Cell concentration and viability were monitored
using Trypan blue in a Neubauer hemocytometer.
The following monoclonal antibodies were used as
indicated by the manufacturers (BD Pharmingen®
(BD, Franklin Lakes, New Jersey, USA)): CD90-PE
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(BD, #561443), CD45-FITC (BD, #347463), CD14-PE (BD,
#555398), CD34-PEcy5 (BD, #561819), CD31-PE
(BD, #555446), IgG-FITC (BD, #555786), HLA-DR-FITC
(BD, #555558), CD166-PE (BD, #560903), CD44-PE (BD,
#555479), CD54-PEcy5 (BD, #555512), CD146-PE (BD,
#559263). Isotype controls were used for determining
nonspecific binding and defining cut-off values. A mini-
mum of 20,000 events were acquired on a BD FACS
Calibur® flow cytometer and results were analyzed using
CellQuest™ software.
Differentiation assays
Pre-cultured cells were seeded into 24-well plates (1 mL/well)
at 13,157 cells/cm2 (adipogenic differentiation), 5,263
cells/cm2 (osteogenic differentiation) or cultured as pellets
containing 1 × 105 cells (chondrogenic differentiation).
Differentiation medium was replaced twice a week.
Adipogenic medium
LG-DMEM supplemented with 10% FBS, 1 μM dexametha-
sone, 0.5 mM 3-Isobutyl-1-methylxanthine, 10 μM human
insulin (Humulin-N®, Eli Lilly and Company, Indianapolis,
Indiana, USA), 0.2 mM indomethacin and a penicillin/
streptomycin solution at 100 U/mL and 100 μg/mL,
respectively.
Osteogenic medium
LG-DMEM supplemented with 10% FBS, 10 nM dexa-
methasone, 10 mM β-glycerophosphate, 50 μM L-ascorbic
acid 2-phosphate and penicillin/streptomycin (all reagents
obtained from Sigma-Aldrich, St. Louis, Missouri, USA) at
100 U/mL and 100 μg/mL, respectively.
Chondrogenic medium
LG-DMEM supplemented with 1% FBS, 50 μg/mL L-
ascorbic acid 2-phosphate, 10 ng/mL transforming growth
factor-β3, 0.169 UI/mL human insulin and 6.25 μg/mL
human transferrin.
After 17 to 21 days, cell cultures were fixed in formalin
buffer and washed with PBS. Intracellular accumulated lipids
were stained with 0.5% Oil Red O solution. Calcium deposits
were stained with 1% Alizarin Red S solution, pH 4.2. Glycos-
aminoglycans were stained with 1% toluidine blue solution.
Cytokine, growth factor and extracellular matrix
quantification
We quantified cell supernatant concentration of 49 different
cytokines, growth factors and extracellular matrix-related
proteins: pro-inflammatory cytokines (GM-CSF, IL-1β, IL-6,
IL-8, TNF-α, IFN-γ, IL-2, IL-2R, IL-7, IL-12p40/p70, IL-15
and IL-17), anti-inflammatory cytokines (IL-1RA, IL-4, IL-5,
IL-10, IL-13 and IFN-α,), chemokines (eotaxin, IP-10,
MCP-1, MIG, MIP-1α, MIP-1β and RANTES),angiogenic growth factors (VEGF, VEGF-D, endostatin,
aFGF, thrombospondin-2, angiopoietin-1, angiogenin and
PLGF), matrix metalloproteinases (MMP-1, -3, -7, -8 and
-13) and growth factors (EGF, HGF, bFGF, G-CSF, TGF-β1,
TGF-β2, TGF-β3, PDGF-AA, PDGF-AB, PDGF-BB and
IGF-1). Commercial Luminex kits were used: Human
Cytokine 30-plex Assay (Invitrogen, Carlsbad, California,
USA), Fluorokine MAP TGF-β Multiplex Kit (R&D,
Minneapolis, Minnesota, USA), Human Angiogenesis
Fluorokine Multi Analyte Profiling Kit (R&D, USA), Fluor-
okine MAP Human MMP kit (R&D, USA) and Milliplex
MAP Human IGF-1 Single Plex Kit (Millipore, Billerica,
Massachusetts, USA). Only PDGF-AB was quantified
using an ELISA kit: Quantikine hPDGF-AB ELISA (R&D,
USA). Procedures were performed according to the manu-
facturers’ instructions.
Extracellular matrix proteins were also quantified in su-
pernatants using commercial ELISA kits and following the
manufacturers’ instructions: heparan sulphate (E0623h,
EIAab, Wuhan, Hubei, China), aggrecan (E91908Hu,
USCN, Wuhan, Hubei, China), decorin (E92127Hu,
USCN, USA), elastin (E91337Hu, USCN, USA), laminin
(E90082Hu, USCN, USA), perlecan (E82748Hu, USCN,
USA), fibronectin (E90037Hu, USCN, USA) and collagens I
(E90571Hu, USCN, USA), II (E90572Hu, USCN, USA), III
(E90176Hu, USCN, USA), IV (E90180Hu, USCN, USA).
We analyzed cell supernatants obtained from prolifera-
tion experiments at Day 8 (end of the exponential growth
phase). Quantified supernatants contained FBS, so FBS-
supplemented media were also quantified. In order to
make results comparable, concentrations were normalized
by cell concentration and culture time, therefore express-
ing them in pg/106 cells/day.Statistical analysis
Results were expressed as mean ± standard deviation for at
least three replicates. Statistical significance was assessed by
one-way non-parametric analysis of variance followed
by the Bonferroni test (to compare the three groups).
P-values <0.05 were considered statistically significant. Stat-
istical analyses were performed using the Prism 5.00 Soft-
ware (GraphPad Software Inc., San Diego, California, USA).Results
Cell proliferation
Proliferation curves are shown in Figure 1 and cumulative
proliferation times are shown in Table 1. WJ-MSC showed
a higher proliferation potential, achieving a final cell con-
centration four times higher than AT- and BM-MSC after
eight days. A slight decrease in cell proliferation was ob-
served for all cell types after nine days in culture, as ex-
pected since the number of cell doublings is increasing
and cell culture media nutrients are slowly depleted.
Figure 1 Proliferation curves of human mesenchymal stromal
cells in α-MEM supplemented with 10% fetal bovine serum.
BM-MSC: Bone marrow-derived mesenchymal stromal cells, AT-MSC:
adipose tissue-derived mesenchymal stromal cells; WJ-MSC:
Wharton’s Jelly-derived mesenchymal stromal cells, α-MEM,
alpha-Minimum Essential Medium.
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dominate in a long term culture of cell pools. Consider-
ing the duplication time of human MSC, an excessive
proliferation of a single “strong” clone would take longer
than the extension of our experiment, and we therefore
assume that the pool is homogeneous during our eight-
day proliferation curve.Immunophenotyping
Cell cultures in 10% FBS-supplemented medium were
analyzed regarding cell surface markers expression by
flow cytometry. Results are shown in Table 2. Cell sur-
face marker expressions were similar for all cell types,
except CD54 and CD146. CD54 was expressed in 40.0 ±
11.5% BM-MSC, 4.6 ± 3.7% AT-MSC and 97.2 ± 1.7%
WJ-MSC. CD146 expression was higher for WJ-MSCTable 1 Cumulative population doubling times for
mesenchymal stromal cells grown in α-MEM
supplemented with 10% FBS
Time (hours) BM-MSC AT-MSC WJ-MSC
96 79.5 ± 16.1 59.8 ± 3.3 28.4 ± 3.6
144 79.7 ± 2.1 51.5 ± 3.4 34.0 ± 1.8
192 88.4 ± 8.1 63.5 ± 6.6 38.4 ± 1.7
Cell pools were plated in 24-well plates at a concentration of 6,000 cells/mL
and were trypsinized and counted after 96, 144 and 192 hours.
FBS: fetal bovine serum, α-MEM: alpha-Minimum Essential Medium, AT-MSC:
adipose tissue-derived mesenchymal stromal cells, BM-MSC: bone
marrow-derived mesenchymal stromal cells; WJ-MSC: Wharton’s Jelly-derived
mesenchymal stromal cells (WJ-MSC).(90.0 ± 6.0%) and BM-MSC (81.7 ± 4.4%) and lower in
AT-MSC (24.9 ± 3.4%).
Cell differentiation
All three cell types were differentiated into adipogenic,
osteogenic and chondrogenic cell phenotypes (Figure 2).
AT- and BM-MSC showed a higher adipogenic poten-
tial when compared to WJ-MSC. Regarding osteogenic
potential, AT-MSC showed the highest calcium depos-
ition, judging by Alizarin Red S staining. BM-MSC re-
vealed a higher staining for glycosaminglycan with
toluidine blue solution but pellet size was smaller than
AT- and WJ-MSC.
Cytokine, growth factor and extracellular matrix
quantification
Results from chemokine quantification in cell super-
natant of MSC cultures are shown in Figure 3. Among
the quantified chemokines, only MIG and MIP-1α were
not detected in any supernatant. RANTES was secreted
only by AT- and WJ-MSC, with WJ-MSC secretion be-
ing 5.4 times higher than AT-MSC. AT- and BM-MSC
did not secrete MIP-1β in detectable concentrations;
only WJ-MSC secreted this chemokine, but in a low
concentration (1.8 ± 1.3 pg/106 cells/day). MCP-1 secre-
tion was similar for BM- and AT-MSC and was signifi-
cantly higher for WJ-MSC (WJ-MSC secretion was 17.2
and 9.6 times higher than BM- and AT-MSC, respect-
ively). IP-10 secretion was also higher in WJ-MSC, but
AT-MSC secreted the highest eotaxin concentration.
Comparing all three cell lines, WJ-MSC secreted higher
chemokine concentrations. BM-MSC secreted the lowest
amount of all chemokines, suggesting a low capacity of
cell mobilization into the tissue.
Considering anti-inflammatory cytokines, only IL-1RA
was detected in all three cell types, with WJ-MSC secret-
ing the highest concentration (35.2 and 3.7 times higher
than BM- and AT-MSC, respectively; Figure 4). IFN-α was
not secreted by AT- and BM-MSC in FBS-supplemented
media in detectable concentrations; only WJ-MSC se-
creted 22.20 ± 0.01 pg IFN-α/106 cells/day. Therefore, WJ-
MSC showed the stronger anti-inflammatory profile.
A total of 12 pro-inflammatory cytokines were quanti-
fied in all three cell culture supernatants. GM-CSF,
TNF-α, IFN-γ, IL-1β, IL-2, IL-2R, IL-15 and IL-17 were
not detected in any of them. WJ-MSC secreted the high-
est concentrations of IL-6 and IL-8 and AT-MSC the
highest amounts of IL-7 and IL-12; BM-MSC secreted
all four cytokines, but in a lower concentration. These
results again confirmed the pro-inflammatory profile of
WJ-MSC and the anti-inflammatory behavior of BM-
MSC. Results are shown in Figure 5.
The growth factors EGF, bFGF, TGF-β3, PDGF-AB
and IGF-1 were not detected in any supernatant,
Table 2 Quantification of cell surface markers by flow cytometry
Marker BM-MSC AT-MSC WJ-MSC
CD73 99.0 ± 0.9 (65.3 ± 8.6) 92.3 ± 7.0 (153.3 ± 95.4) 96.4 ± 3.3 (283.7 ± 259.6)
CD90 98.3 ± 0.8 (125.9 ± 63.6) 97.0 ± 3.1 (203.6 ± 94.7) 99.5 ± 0.4 (295.4 ± 79.2)
CD105 94.3 ± 7.3 (66.0 ± 44.3) 94.3 ± 5.7 (142.4 ± 78.8) 87.4 ± 11.7 (151.3 ± 196.0)
CD45 0.8 ± 0.9 (3.5 ± 1.6) 0.6 ± 0.7 (11.3 ± 11.0) 1.1 ± 1.1 (7.9 ± 3.8)
CD14 1.5 ± 0.8 (2.6 ± 0.8) 0.8 ± 1.0 (13.6 ± 0.1) 0.9 ± 0.7 (8.3 ± 4.4)
CD34 0.7 ± 0.6 (2.8 ± 1.6) 0.7 ± 0.9 (2.6 ± 2.1) 2.6 ± 2.7 (8.7 ± 4.7)
CD31 0.9 ± 1.1 (10.1 ± 7.9) 0.3 ± 0.5 (3.0 ± 1.0) 1.3 ± 2.0 (5.9 ± 5.5)
CD44 99.6 ± 0.2 (233.2 ± 58.1) 99.3 ± 0.1 (1,036.0 ± 1,306.4) 95.6 ± 5.4 (231.7 ± 118.3)
CD54 40.0 ± 11.5 (6.0 ± 1.9) 4.6 ± 3.7 (5.7 ± 4.8) 97.2 ± 1.7 (81.3 ± 94.7)
CD146 81.7 ± 4.4 (26.5 ± 24.4) 24.9 ± 3.4 (38.9 ± 10.6) 90.9 ± 6.0 (110.4 ± 48.4)
CD166 94.7 ± 7.8 (71.2 ± 17.8) 72.4 ± 29.9 (143.2 ± 59.1) 91.0 ± 3.6 (118.9 ± 8.8)
HLA-DR 1.8 ± 2.4 (6.0 ± 6.3) 1.1 ± 1.2 (29.1 ± 17.9) 1.1 ± 1.1 (8.0 ± 3.2)
IgG 0.7 (8.24) 0.6 ± 0.0 (7.3 ± 5.1) 0.6 (22.8)
Results are expressed in mean percentage ± standard deviation, with MPI values in brackets. AT-MSC: adipose tissue-derived mesenchymal stromal cells, BM-MSC:
bone marrow-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
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detection limit of the corresponding assays. PDGF-AA
was secreted by all cells under FBS-supplemented media
(Figure 6). PDGF-BB was only secreted by BM-MSC, but
in a low concentration (1.6 ± 0.8 pg/106 cells/day). High-
est concentrations of HGF, TGF-β2 and PDGF-AA were
secreted by WJ-MSC. Best producers of TGF-β1 were
AT-MSC, but the difference with BM- and WJ-MSCFigure 2 Cell differentiation assays of human mesenchymal stromal c
After 21 days, intracellular accumulated lipids were stained with Oil Red O,
glycosaminoglycans were stained with toluidine blue. BM-MSC: bone marro
mesenchymal stromal cells,WJ-MSC: Wharton’s Jelly-derived mesenchymalsecretion was not significant. G-CSF was secreted only
by WJ-MSC at a rate of 28.8 ± 9.1 pg/106 cells/day. Con-
sidering the whole growth factor family here quantified,
WJ-MSC showed the highest mitogenic profile.
Results regarding concentration of angiogenic factors in
cell supernatants are shown in Figure 7. All the studied an-
giogenic factors were found in supernatants of the three cell
types, except VEGF-D that was only detected in BM-MSCells to the adipogenic, osteogenic and chondrogenic phenotypes.
calcium deposits were stained with 1% Alizarin Red S and
w-derived mesenchymal stromal cells, AT-MSC: adipose tissue-derived
stromal cells.
Figure 3 Concentration of chemokines (RANTES, MCP-1, eotaxin and IP-10) in human mesenchymal stromal cell supernatants. Values
are expressed as average ± standard deviation of three replicates. Statistical significance difference was determined by analysis of variance
followed by the Bonferroni post-hoc test (n = 3, α = 0.05). BM-MSC: bone marrow-derived mesenchymal stromal cells, AT-MSC adipose
tissue-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
Figure 4 IL-1ra concentration in human mesenchymal stromal
cell supernatants. Values are expressed as average ± standard
deviation of three replicates. Statistical significance difference was
determined by analysis of variance followed by the Bonferroni
post-hoc test (n = 3, α = 0.05). BM-MSC: bone marrow-derived
mesenchymal stromal cells, AT-MSC adipose tissue-derived
mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived
mesenchymal stromal cells.
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creted very low concentrations of VEGF, 4,070 and 4,614
times lower than BM- and AT-MSC, respectively. All three
cell types showed similar angiopoietin-1 concentrations in
their supernatants. AT-MSC secreted the highest amounts
of angiogenin, PLGF and aFGF. Thrombospondin-2 secre-
tion by WJ-MSC was 3.2 and 6.8 times higher than AT-
and BM-MSC, respectively, and endostatin concentration
in WJ-MSC was also higher than AT- and BM-MSC (1.8
and 7.2 times, respectively). Considering these results we
can conclude that BM-MSC have a lower angiogenic poten-
tial, and that AT- and WJ-MSC are more angiogenic but
their effects might be different since they secreted a differ-
ent panel of angiogenic factors.
All the studied extracellular matrix proteins were de-
tected (Figure 8). AT-MSC secreted higher concentra-
tions of collagen I, II and III. AT-MSC were also the
only cell types able to secrete collagen IV at detectable
concentrations (190.1 ± 48.8 pg/106 cells/day). Fibronectin
was not detected in any supernatant. BM-MSC secreted
significantly higher amounts of heparan sulfate. Elastin and
aggrecan concentrations in BM-MSC supernatants were
also higher than in AT- and WJ-MSC, but these differences
were not statistically significant. WJ-MSC did not secrete
decorin, laminin, fibronectin, heparan sulfate, collagen II
Figure 5 Concentration of secreted pro-inflamatory cytokines (IL-6, IL-7, IL-8 and IL-12) in mesenchymal stromal cell supernatants.
Values are expressed as average ± standard deviation of three replicates. Statistical significance difference was determined by analysis of variance
followed by the Bonferroni post-hoc test (n = 3, α = 0.05). BM-MSC: bone marrow-derived mesenchymal stromal cells, AT-MSC adipose
tissue-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
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AT-MSC are an excellent collagen-secreting cell type and
WJ-MSC secrete a limited amount of extracellular matrix
components.
Metalloproteinase concentrations are shown in Figure 9.
AT-MSC secreted the highest concentrations of MMP1
(collagenase 1) and MMP3 (stromelysin 1). None of the
three cell types secreted MMP7 (matrilysin). MMP8 (col-
lagenase 2) was secreted by BM-MSC only (50.3 ± 16.8
pg/106 cells/day). MMP13 (collagenase 3) secretion was
only quantified in AT-MSC supernatants (25.6 ± 0.1 pg/106
cells/day).
Results from all proteins quantified are also shown in
Additional file 1: Table S1.
Discussion
The present study was done to compare biological pa-
rameters of the three MSC isolated from the most fre-
quently used tissue sources: bone marrow, adipose tissue
and Wharton’s Jelly of the umbilical cord, under the
basal conditions of in vitro cell culture using synthetic
media and fetal bovine serum. This first study is being
pursued by in vitro analyses under conditions more closely
representative of the in vivo tissue environments found incell therapies using MSC. We describe the character-
ization of a representative range of secreted proteins by
three mesenchymal stromal cells, isolated from different
human tissues. The proposal is the selection of the most
appropriate type of MSC for a specific therapy, since key
characteristics are needed for the cells to effectively
participate in tissue regeneration for a particular disease.
For example, for cartilage-regenerating therapies, a cell se-
creting high amounts of cartilage-specific components of
the extracellular matrix would be desired; ischemic dis-
eases should be ideally treated with a cell showing anti-
inflammatory and pro-angiogenic potential, in order to
control the inflammatory environment and to promote the
re-vascularization of the affected area. Our results con-
firmed that mesenchymal cells derived from different ori-
gins have different properties in terms of pro-regenerative,
pro-angiogenic or anti-inflammatory activities. Analyses of
the behavior of the three different MSC studied here may
indicate the good choice of the type of the MSC to be used
in each therapy.
Nowadays, MSC are used in regenerative medicine in
two contexts: autologous and allogeneic. In the former
one, integration of MSC into the regenerating tissues is
sought, and the capacity of proliferation and production
Figure 6 Growth factor concentration (PDGF-AA, HGF, TGF-β1 and TGF-β2) in human mesenchymal stromal cell supernatants. Values
are expressed as average ± standard deviation of three replicates. Statistical significance difference was determined by analysis of variance
followed by the Bonferroni post-hoc test (n = 3, α = 0.05). BM-MSC: bone marrow-derived mesenchymal stromal cells, AT-MSC adipose
tissue-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
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long term integration of MSC is not expected, even if
MSC express only low levels of the histocompatibility
markers. Their anti-inflammatory activity and their
capacity to activate resident stem cells and mobilize the
circulating ones into the regenerating tissues are thus
relevant.
We evaluated MSC proliferation and we confirmed that
WJ-MSC have a higher proliferation rate, results that were
already reported by other authors [17,22,23]. This is ex-
pected since WJ-MSC are of fetal origin, and the cell pro-
liferation decreases sharply with maturation of the donor.
With a rare exception of the cryopreserved cells of the
Wharton’s Jelly for future use in which autologous cells
may be available, their use is at present essentially dedi-
cated to the allogeneic use. Nevertheless, their availability
at the perinatal period may be considered in therapy of
preterm birth, repair of inborn defects and in perinatal
accidents, and, in view of their high protrophic and angio-
genic capacity described in the present study, they may
offer promising solutions [24,25].
The relatively high expression of CD54 and CD146 in
WJ-MSC may be consistent with the proposal of their high
potential in regenerative medicine. The CD54 (ICAM-1)
is an adhesion molecule that upon stimulation with pro-inflammatory mediators promotes mobilization and trans-
endothelial migration of circulating cells into injured tissues
[26]. CD146 (MCAM, MUC18) is a cell adhesion molecule,
whose high expression on MSC is associated with greater
differentiation potential [27].
When considering an inflammatory profile, WJ-MSC se-
creted the highest concentrations of RANTES, MCP-1
and IP-10, chemokines able to attract a wide range of
inflammatory cells (monocytes, macrophages, dendritic
cells, T lymphocytes). IL-6 was secreted at higher concen-
trations by WJ-MSC, but all three cells secreted high IL-6
concentrations: while plasmatic concentration in healthy
patients varied from 0.02 up to 10.1 pg/mL [28], IL-6 con-
centration in cell supernatants was much higher: 697.6 ±
232.8 pg/mL for BM-MSC, 620.7 ± 49.4 for AT-MSC and
4,001.0 ± 1,484.1 for WJ-MSC. IL-6 was recently associ-
ated with MSC pluripotency and immunoprivilege: BM-
MSC differentiation induced loss of immune privilege
and down-regulation of IL-6 secretion [29,30]. Nasir and
colleagues demonstrated that a combination of BM-MSC
and IL-6 is much more effective in attenuating liver fibro-
sis than BM-MSC alone [31], and this result makes us
suggest that maybe WJ-MSC alone would be a more ap-
propriate candidate for this therapy, since these cells
secrete higher IL-6 concentrations.
Figure 7 Concentration of angiogenic factors in human mesenchymal stromal cell supernatants. In this study we quantified angiopoietin-1,
angiogenin, thrombospondin-2, VEGF, aFGF, PLGF, endostatin. Values are expressed as average ± standard deviation of three replicates.
Statistical significance difference was determined by analysis of variance followed by the Bonferroni post-hoc test (n = 3, α = 0.05). BM-MSC:
bone marrow-derived mesenchymal stromal cells, AT-MSC adipose tissue-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived
mesenchymal stromal cells.
Amable et al. Stem Cell Research & Therapy 2014, 5:53 Page 9 of 13
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longs to the IL-1 cytokine family, a group of at least 11
inflammatory mediators. IL1-RA has already been
described as a therapeutic candidate for diabetes
mellitus II treatment, because of its protective effects:
IL1-RA prevented pancreatic mononuclear cell infiltra-
tion, islet destruction and hyperglycemia in a model of
induced diabetes mellitus [32]. In pre-clinical studies in
mice, Ortiz and coworkers demonstrated that BM-MSC
had an anti-inflammatory and anti-fibrotic effect and
that this effect was mainly mediated by IL1-RA; they
also demonstrated that BM-MSC were more effective
than recombinant IL1-RA [33]. Therefore, this potentialof WJ-MSC, mediated by IL1-RA secretion, should also
be exploited.
IL-8 was secreted in very different concentrations
among different cells: while BM-MSC secreted 47.8 ± 11.7
pg/106 cells/day, and WJ-MSC secreted 19,151.3 ± 5,512.2
pg/106 cells/day, 400 times higher than BM-MSC produc-
tion. A few authors reported increased IL-8 from MSC
when cells were stimulated with lipopolysaccharides
(LPS) [34], but identification of whether IL-8 secretion
would be helpful in a determined MSC application needs
to be studied.
Regarding angiogenic factors, only BM-MSC secreted
detectable amounts of VEGF-D. VEGF-D was defined as
Figure 8 Secreted amounts of extracellular matrix components in human mesenchymal stromal cell supernatants. Here we report
results obtained for collagen I, II and III, elastin, heparan sulfate, decorin, aggrecan and laminin. Values are expressed as average ± standard
deviation of three replicates. Statistical significance difference was determined by analysis of variance followed by the Bonferroni post-hoc
test (n = 3, α = 0.05). BM-MSC: bone marrow-derived mesenchymal stromal cells, AT-MSC adipose tissue-derived mesenchymal stromal cells,
WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
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isoform [35] and it has been tested in phase I clinical tri-
als for myocardial infarction in a gene therapy approach
(ClinicalTrials.gov; Identifier: NCT01002430).
WJ-MSC produced almost undetectable amounts of
VEGF; on the other hand, AT- and BM-MSC were the
highest VEGF producers. Research articles like those
published by Deuse’s and Augustin’s groups showed
that MSC genetically modified to overexpress VEGF are
more appropriate than MSC alone for treating acute myo-
cardial infarction, as VEGF extended MSC survival and pro-
tected them against apoptosis and improved heart function
recovery [36,37]. This information suggests that BM- andAT-MSC would be better candidates for infarction therapy
than WJ-MSC.
Thrombospondin-2 was another angiogenic factor that
was found in high concentrations in all cell culture super-
natants and WJ-MSC secreted the highest amounts. Jeong
and colleagues have shown that WJ-MSC exerted
a regenerative effect on cartilage and they suggested
that this effect was mediated by thrombospondin-2, since
this molecule alone could exert a similar effect and
thrombospondin-2 knock-down in WJ-MSC using siRNA
abolished its chondro-regenerative potential [38]. Con-
sidering that AT-MSC also secreted high concentrations
of thrombospondin-2, they would be a good potential
Figure 9 Concentration of secreted matrix metalloproteinases (MMP1 and MMP3) in human mesenchymal stromal cell supernatants.
Values are expressed as average ± standard deviation of three replicates. Statistical significance difference was determined by analysis of variance
followed by the Bonferroni post-hoc test (n = 3, α = 0.05). BM-MSC: bone marrow-derived mesenchymal stromal cells, AT-MSC adipose
tissue-derived mesenchymal stromal cells, WJ-MSC: Wharton’s Jelly-derived mesenchymal stromal cells.
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into account autologous adipose tissue availability in
cases when the patients did not cryopreserve their own
umbilical cord cells.
Angiopoietin-1 is an important pro-angiogenic factor
involved in vascular maturation and neovasculogenesis.
Similar to what was described for VEGF, genetically
modified MSC expressing angiopoietin-1 were more
effective in regenerating myocardial tissue after in-
farction than MSC alone [39]. Liu and coworkers also
demonstrated that MSC expressed functional receptors
for angiopoietin-1 and that angiopoietin-1 protected
MSC against apoptosis induced by hypoxia and serum
deprivation [40]. Angiopoietin-1 secretion was not sta-
tistically different for all three MSC, but the secretion
rate of WJ-MSC was lower than those of AT- and
BM-MSC.
PLGF displays a high homology with VEGF, binds to the
VEGF receptor and is able to augment the action of VEGF
both in vivo and in vitro. Liu and colleagues showed that
PLGF exerted a neuroprotective and angiogenic effect in
cerebral ischemia: BM-MSC injected intravenously re-
duced lesion volume and induced angiogenesis while im-
proving functional recovery, but the effect was greater
when BM-MSC were genetically modified to over-express
PLGF [41]. Considering our results, AT-MSC secreted
higher concentrations of PLGF: 3.3 and 7.8 times higher
than BM- and WJ-MSC. This origin-related differential of
AT-MSC would make them more appropriate for tissue
regeneration after cerebral ischemia.
When analyzing growth factor secretion, WJ-MSC se-
creted higher amounts of TGF-β2, HGF and PDGF-AA
and was the only cell type secreting G-CSF in detectable
levels. HGF promotes migration, proliferation and survival
of a wide range of cell types and was shown to induce ex-
pression of cardiac-specific markers in MSC [42]. G-CSFis a potent chemotactic factor for MSC and has been
successfully used in different applications, such as acute
myocardial infarction [43] and injured brain [44].
Regarding extracellular matrix components, AT-MSC se-
creted the highest amounts of collagen I, II, III and IV and
WJ-MSC did not secrete any detectable amounts of colla-
gen II and IV. WJ-MSC did not produce fibronectin, hepa-
ran sulphate, decorin, laminin and aggrecan. Collagen II is
the most abundant protein in articular and hyaline cartil-
age; therefore, WJ-MSC would not be appropriate for car-
tilage regeneration since it would generate a fibrous tissue
due to its higher collagen III secretion. Collagen I and elas-
tin are the main components of tendons, making AT-MSC
the most appropriate cell type for tendon regeneration.
MSC are also key players in skin regeneration and aging
prevention: they are attracted by PDGF-BB secreted by
endothelial cells and they increase collagen IV secretion, a
component of basement membranes [45]. AT-MSC were
the only cell type that secreted PDGF-BB in vitro and they
produced the highest amounts of collagen IV, suggesting
they are the most appropriate cell type for skin regener-
ation, since neither BM- nor WJ-MSC secreted PDGF-BB
and collagen IV.
MMP1, MMP3 and MMP13 are important enzymes in-
volved in the degradation of bone, cartilage and tendon.
Serum and synovial levels of MMP1, MMP3 and MMP13
are increased in rheumatoid arthritis and osteoarthritis
[46,47]. Analyzing our results, AT-MSC produced the
highest concentrations of MMP1 and MMP3, this being a
negative point for using AT-MSC in bone, cartilage and
tendon applications. AT- and WJ-MSC secreted high
amounts of MMP1 and MMP3, but low levels or no
MMP13. A good candidate for bone, cartilage and tendon
regeneration, when considering matrix metalloproteinases,
would be BM-MSC, which secreted the lowest concentra-
tions of MMP1 and MMP3 and no MMP13.
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and mitogenic profile, while AT-MSC secreted higher
concentrations of pro-angiogenic proteins, extracellular
matrix components and matrix metalloproteinases. Acquir-
ing a deeper molecular knowledge about MSC from dif-
ferent origins will help us make a more rational and
effective selection of the MSC for different applications
in regenerative medicine.
Conclusions
Our data showed that MSC from different tissues have
different properties in vitro and this can be the reason
for their different behavior in different clinical applica-
tions. In conclusion, cell type for regenerative therapies
should be carefully chosen. The present results need to
be compared with in vivo pre-clinical studies in order to
suggest the best protocols for mesenchymal stromal cell
use in each clinical therapy.
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